Santhera Launches Placement of up to 500,000 New Shares Through an Accelerated Bookbuilding Procedure

Santhera Pharmaceuticals Holding AG / Santhera Launches Placement of up to 500,000 New Shares Through an Accelerated Bookbuilding Procedure . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN

Liestal, Switzerland, December 1 2015 - Santhera Pharmaceuticals (SIX: SANN) announces that it plans to place up to 500,000 new shares from its authorized capital, representing 8.8% of the Company's currently outstanding shares. The proceeds from the share placement will significantly strengthen Santhera's resources to finance ongoing developmental, regulatory and commercial activities with its lead product Raxone^®.

The new shares with a par value of CHF 1.00 per share will be issued from the Company's authorized capital on a non-preemptive basis. New shares are planned to be placed through an accelerated bookbuilding procedure by way of a private placement in Switzerland and abroad in accordance with applicable securities laws. In line with the articles of incorporation, the Board of Directors has excluded the preemptive rights of the existing shareholders.

Santhera has also granted the bookrunners an option to place up to 100,000 additional shares, increasing the potential offer size to up to 600,000 shares. The shares underlying the increase option will also be sourced from the authorized capital.

The price of the placed shares will be determined after the close of the bookbuilding period which is expected to end on December 2, 2015. Trading of the new shares on the SIX Swiss Exchange will commence on or around December 3, 2015. The new shares will be fully fungible and rank pari passu with the Company's existing shares.

"The proceeds from the planned share placement will significantly support the Company's development, regulatory and commercial activities and strengthen its overall financial flexibility," commented Martin Gertsch, Chairman of the Board.

The proceeds of the proposed financing will be mainly used for the:

• ongoing preparations for regulatory filings and market launch in Duchenne muscular dystrophy (DMD) in the US and Europe
• recently announced new clinical trial in DMD patients using glucocorticoid steroids
• launch of Raxone for the treatment of Leber's hereditary optic neuropathy (LHON) in Europe and the implementation of post-approval measures agreed with the European Medicines Agency (EMA)

About Santhera